Email updates

Keep up to date with the latest news and content from Diagnostic Pathology and BioMed Central.

Open Access Highly Accessed Open Badges Research

Hypermethylation of EDNRB promoter contributes to the risk of colorectal cancer

Cheng Chen12, Lingyan Wang3, Qi Liao1, Yi Huang4, Huadan Ye1, Fei Chen1, Leiting Xu1, Meng Ye2* and Shiwei Duan1*

Author Affiliations

1 Zhejiang Provincial Key Laboratory of Pathophysiology, School of Medicine, Ningbo University, Ningbo, Zhejiang 315211, China

2 The Affiliated Hospital, Ningbo University, Ningbo, Zhejiang 315000, China

3 Bank of Blood Products, Ningbo No.2 Hospital, Ningbo, Zhejiang 315010, China

4 Department of Neurosurgery, Ningbo First Hospital, Ningbo University, Ningbo, Zhejiang 315010, China

For all author emails, please log on.

Diagnostic Pathology 2013, 8:199  doi:10.1186/1746-1596-8-199

Published: 10 December 2013



Colorectal cancer (CRC) is one of the most common digestive malignancies in the world. EDNRB is a new candidate tumor suppressor gene which is often down-regulated or even silenced by promoter hypermethylation in various human cancers. However, the function of EDNRB gene in CRC remains unknown. In this study, we examined the expression and DNA methylation of EDNRB in CRC tissues.


A total of 42 paired CRC and adjacent normal tissue samples were used to determine mRNA levels and DNA methylation status of EDNRB gene by qRT-PCR and methylation-specific PCR (MSP), respectively.


Our study showed that EDNRB promoter hypermethylation was more frequently in CRC tissues than in the normal tissues (92.86 versus 59.52, p = 0.001). Consequently, significantly lower level of EDNRB mRNA was found in CRC tumor samples than in normal samples (0.31 ± 0.91 versus 0.70 ± 1.18, p = 0.032).


Our results suggested that EDNRB promoter hypermethylation might downregulate its gene expression in CRC, and thus played an important role in the development of CRC.

The virtual slide

The virtual slides for this article can be found here: webcite

Colorectal cancer; EDNRB; DNA methylation; Biomarker